Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 9.00% is 12% above its 5-year average of 8.06%, near the high end of its 5-year range (-2.26%–12.49%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.40% above its 12-month average of 8.70%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 9.00%.
RETURN ON EQUITY (ROE)
9.00%
RETURN ON EQUITY (ROE) AVG TTM
8.70%
RETURN ON EQUITY (ROE) AVG 3Y
9.06%
RETURN ON EQUITY (ROE) AVG 5Y
8.06%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.40%
CURRENT VS 3Y AVG
-0.66%
CURRENT VS 5Y AVG
+11.58%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 677 covered companies
CURRENT VS SECTOR MEDIAN
+122.08%
vs the sector median at left
The Pennant Group, Inc.
Market Cap
$1.41B
Return on Equity (ROE)
9.00%
TTM Avg
8.70%
3Y Avg
9.06%
5Y Avg
8.06%
Market Cap
$1.42B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
-244.46%
3Y Avg
-323.47%
5Y Avg
-258.47%
Market Cap
$1.39B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.44B
Return on Equity (ROE)
-29.48%
TTM Avg
-5.20%
3Y Avg
-280.62%
5Y Avg
-280.62%
Market Cap
$1.44B
Return on Equity (ROE)
N/A
TTM Avg
247.90%
3Y Avg
18.71%
5Y Avg
1.58%
Market Cap
$1.45B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Return on Equity (ROE)
-7.08%
TTM Avg
-0.64%
3Y Avg
-1.30%
5Y Avg
-2.08%
Market Cap
$1.46B
Return on Equity (ROE)
23.70%
TTM Avg
9.74%
3Y Avg
8.98%
5Y Avg
11.20%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.41B | 9.00% | 8.70% | 9.06% | 8.06% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | -244.46% | -323.47% | -258.47% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | N/A | 41.79% | 41.79% | 41.79% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | -29.48% | -5.20% | -280.62% | -280.62% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | 247.90% | 18.71% | 1.58% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.46B | -7.08% | -0.64% | -1.30% | -2.08% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 23.70% | 9.74% | 8.98% | 11.20% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | -32.43% | -24.32% | 8.11% | 8.11% |
ROE
9.0%
ROA
3.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 9.00% |
| 2026-03-31 | 8.76% |
| 2025-12-31 | 8.89% |
| 2025-09-30 | 8.29% |
| 2025-06-30 | 8.56% |
| 2025-03-31 | 8.38% |
| 2024-12-31 | 7.69% |
| 2024-09-30 | 12.49% |
| 2024-06-30 | 12.43% |
| 2024-03-31 | 11.17% |
| 2023-12-31 | 9.53% |
| 2023-09-30 | 9.30% |
| 2023-06-30 | 10.06% |
| 2023-03-31 | 6.01% |
| 2022-12-31 | 5.49% |
| 2022-09-30 | 0.88% |
| 2022-06-30 | -2.26% |
| 2022-03-31 | 2.43% |
| 2021-12-31 | 2.45% |
| 2021-09-30 | 8.09% |
| 2021-06-30 | 11.39% |
| 2021-03-31 | 13.69% |
| 2020-12-31 | 16.30% |
| 2020-09-30 | 8.87% |
| 2020-06-30 | 6.11% |
| 2020-03-31 | 5.50% |
| 2019-12-31 | 3.58% |
| 2019-09-30 | 14.23% |
| 2019-06-30 | 17.68% |
| 2019-03-31 | 22.25% |
| 2018-12-31 | 28.08% |
